Importantly, NSCLC with METex14 skipping is associated with poor prognosis, as the median overall survival for patients with these mutations when treated with MET tyrosine kinase inhibitors (MET-TKIs) is 24.6 months, while for those not receiving MET-TKIs it is 8.1 months [6]. This evidence concerns the gene MET and non-small cell lung carcinoma.